6 active not recruiting. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 6 |
Follow Radiologic Examination: new trials by email Literature Review of Radiologic Examination trials Research Report on Radiologic Examination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) Biopsy Procedure, Biospecimen Collection, Copanlisib - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 22 | 2018-10-08 | 2026-10-19 |
| Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2017-03-23 | 2026-07-30 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) Biopsy Procedure, Biospecimen Collection, Crizotinib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 44 | 2016-07-29 | 2026-03-19 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) Biopsy Procedure, Biospecimen Collection, Crizotinib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2016-07-20 | 2026-10-19 |
| Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2016-01-08 | 2026-09-15 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
Lymphoma (4) · Multiple Myeloma (4) · Hematologic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Lung Neoplasms (1) · Melanoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
National Cancer Institute (NCI) (6)
United States (6) · Guam (1) · Puerto Rico (1)
David S Hong (2) · Jordi Rodon Ahnert (1) · Keith T Flaherty (1) · Lecia V Sequist (1) · Roisin M Connolly (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38433347, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 41556942
U10CA180820 (6), U24CA196172 (1)